1. Home
  2. ALCO vs LYEL Comparison

ALCO vs LYEL Comparison

Compare ALCO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alico Inc.

ALCO

Alico Inc.

N/A

Current Price

$39.56

Market Cap

297.3M

Sector

N/A

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$11.96

Market Cap

320.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALCO
LYEL
Founded
1960
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
297.3M
320.1M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
ALCO
LYEL
Price
$39.56
$11.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$44.00
$30.60
AVG Volume (30 Days)
12.3K
92.9K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
0.49%
N/A
EPS Growth
N/A
N/A
EPS
1.32
N/A
Revenue
N/A
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8,712.13
P/E Ratio
$30.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$31.32
$11.47
52 Week High
$45.01
$45.00

Technical Indicators

Market Signals
Indicator
ALCO
LYEL
Relative Strength Index (RSI) 47.42 35.26
Support Level $37.31 $11.59
Resistance Level $40.01 $14.14
Average True Range (ATR) 0.74 0.81
MACD -0.06 -0.30
Stochastic Oscillator 18.90 4.37

Price Performance

Historical Comparison
ALCO
LYEL

About ALCO Alico Inc.

Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: